Data lacking on prevention of Alzheimer's, cognitive decline

Traynor, Kate
June 2010
American Journal of Health-System Pharmacy;6/15/2010, Vol. 67 Issue 12, p958
Academic Journal
The article offers information on the prevention of Alzheimer's disease and cognitive decline. It discusses a convention held by the National Institutes of Health in Bethesda, Maryland in which the expert panel analyzed scientific evidence on the use of medications and other therapies for prevention of the conditions. It mentions that there is an absence of standardized methods for the diagnosis of both conditions. It further advises the patients to control vascular risk factors.


Related Articles

  • Orphan Diseases. Cerami, Anthony // Sciences;Feb79, Vol. 19 Issue 2, p22 

    Reports the failure of the pharmaceutical industry in supporting the development of new drugs for the cure of orphan diseases in the United States. Role of the National Institute of Health in attacking orphan diseases; Researches for the cure of sickle cell anemia; Clinical picture of...

  • NIH TRND program announces next round of drug development projects.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p622 

    The article reports on the drug development projects of the National Institutes of Health's Therapeutics for Rare and Neglected Diseases (TRND) program. It notes that the drug development project include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, and a...

  • Research for the Real World. Farahani, Pendar // Applied Clinical Trials;Sep2006, Vol. 15 Issue 9, p82 

    The article focuses on the identification of various technologies and discoveries to integrate into the therapeutic development process based on Critical Path initiative of Food and Drug Administration and Roadmap initiatives of the National Institutes of Health in the U.S. The implementation of...

  • FDA plans to improve and accelerate product reviews. Fox, Jeffrey L. // Nature Biotechnology;May2004, Vol. 22 Issue 5, p495 

    The article reports that officials of the U.S. Food and Drug Administration (FDA) on March 16, 2004 launched an effort to accelerate products into and through the drug regulatory system. Agency officials are promising to work with scientists in industry, at other federal agencies such as the...

  • LEGAL HERBS.  // American Herb Association Quarterly Newsletter;Winter2008, Vol. 23 Issue 4, p6 

    The article offers news briefs related to botanical studies in the U.S. Investigations on medicinal herbs are underway at five botanical research centers funded by the National Institute of Health (NIH). The Food and Drug Administration (FDA) amended existing health claims to include the...

  • Halted HRT study ups the alternatives. Yen, Hope // Marketing News;9/16/2002, Vol. 36 Issue 19, p17 

    This article reports that the U.S. National Institute of Health's (NIH) decision in July 2005, to halt a study involving Prempro, a combination of estrogen and progestin, is prompting many baby boomer women to rethink their use of hormone replacement therapy. The government's decision has...

  • An FDA guide to choosing medical treatments. Stehlin, Isadora B. // FDA Consumer;Jun95, Vol. 29 Issue 5, p10 

    Presents a guide on selecting an appropriate medical treatment for a particular disease. Controlled clinical trials conducted by the Food and Drug Administration; Difference of alternative medicine from mainstream American medicine; Alternative therapies under study with grants from the...

  • Receptor research. Jesitus, John // Dermatology Times;Mar2011, Vol. 32 Issue 3, p28 

    The article focuses on peroxisome proliferator-activated receptor (PPAR) gamma. University of California, San Francisco professor Vera H. Price says that the PPAR in cicatricial alopecia (CA) was noted by scalp biopsies of lichen planopilaris (LPP) patients. Pratima Karnik of Case Western...

  • Confounding Interaction of PTC124, Luciferase Reporter. Breindl, Anette // BioWorld Today;2/4/2009, Vol. 20 Issue 22, p1 

    The article reports on the findings by researchers from the U.S. National Institutes of Health (NIH) showing that PTC-124, the experimental drug from PTC Therapeutics Inc., interacts directly with the luciferase protein, the assay system that was first used to identify PTC124 as a drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics